Alicia Schiavi serves as Associate Director of Clinical Operations at Thryv Therapeutics, bringing more than a decade of experience in clinical research and drug development across rare diseases, oncology, and early-phase programs.

Alicia began her career as a Clinical Research Coordinator in gynecology and oncology, where she led principal investigator–initiated studies and supported the execution of multiple clinical trials. She later joined IQVIA (formerly Quintiles), managing multiple sponsor accounts and overseeing the activation and startup of numerous clinical sites.

She subsequently joined Chinook Therapeutics, where she contributed to the development of therapies for IgA nephropathy. In this role, she supported a Phase 1/2 clinical program and advanced to lead startup activities for a subsequent Phase 3 trial.

Prior to joining Thryv, Alicia served as Director of Clinical Operations at Mesentech, where she successfully completed a first-in-human study and led clinical startup activities for programs in osteoporosis and Duchenne muscular dystrophy. In addition, she played a key role in corporate fundraising efforts, strategic development initiatives, and the management of clinical due diligence activities.

Alicia holds a bachelor’s degree in microbiology and Immunology and a master’s degree in human genetics from McGill University.